October 25, 2021 -- Canbridge Pharmaceuticals has signed an exclusive global research collaboration and licensing agreement with Scriptr Global for that company's Stitchr ribozyme-mediated RNA assembly platform for the development of gene therapies for dystrophinopathies.
Under the agreement, Scriptr Global will conduct research, and Canbridge will be responsible for development, manufacturing, regulatory clearance, and marketing, it said. Financial terms of the agreement include an upfront payment, development and sales payments upon hitting certain milestones, as well as royalties based on net sales.
Dystrophinopathies are X-linked genetic muscular diseases such as Duchenne muscular dystrophy, Becker muscular dystrophy, and Duchenne muscular dystrophy-associated dilated cardiomyopathy, according to Canbridge.
Copyright © 2021 scienceboard.net